Prothena Corp (PRTA)

• Market cap: $535M
• 1 day: -2.46%
• 5 days: -8.9%
• 1 month: -1.88%
• 3 months: 23.2%
• 6 months: 44.12%
• Year to date: -27.36%
• 1 year: -38.32%
• 5 years: -19.92%
• 10 years: -85.24%
• Sector: Healthcare
• Industry: Biotechnology

About: Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Employees: 163